PROCALCITONIN, INTERLEUKIN-10, AND CD64 AS MARKERS OF NEONATAL SEPSIS

降钙素原、白细胞介素 10 和 CD64 作为新生儿败血症的标志物

• 批准号: 7604923
• 负责人: EDWARD F BELL
• 金额: $ 0.13万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604923
• 关键词: Birth Weight; C-reactive protein; Cessation of life; Computer Retrieval of Information on Scientific Projects Database; Early Diagnosis; Funding; Grant; Infant; Infection; Institution; Interleukin-10; Life; Low Birth Weight Infant; Morbidity - disease rate; Neonatal; Newborn Infant; Pattern; Research; Research Personnel; Resources; Sepsis; Source; Time; United States National Institutes of Health; Work; day; mortality; postnatal; procalcitonin

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Bacterial sepsis continues to be a major cause of morbidity and mortality in newborns, particularly in low-birth-weight infants. Four percent of deaths in the first 3 days of postnatal life and 45% of deaths are related to infections, with no change in this pattern for the last 15 years. Bacterial sepsis occurs in 1% to 10% of term newborns and is up to 50 times more common in infants with a birth weight <800 g. Aim of the work: to evaluate markers, namely Procalcitonin, IL-10, CD 64, and C-reactive protein for early diagnosis of neonatal sepsis and to identify the optimal cut off value of each marker.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 细菌性败血症仍然是新生儿发病率和死亡率的主要原因，特别是在低出生体重婴儿中。出生后头3天的死亡中有4%与感染有关，45%的死亡与感染有关，这一模式在过去15年中没有变化。细菌性败血症发生在1%至10%的足月新生儿中，在出生体重为800克的婴儿中，细菌败血症的发生率高达50倍。 目的：评价降钙素原、IL-10、CD-和C-反应蛋白在新生儿败血症早期诊断中的价值，并确定各指标的最佳临界值。